BenevolentAI Investor Day Presentation Deck

BEN-2293 - Phase Ib safety and tolerability study successfully completed Phase Ib/Ila double-blind, placebo-controlled, first-in-patient, two-part clinical study Phase Ib 3 First-in-human dose escalation 2 Phase Ib completed Dec 2021 8 Mild-Moderate AD patients (18-65 years) per cohort, randomised 3:1 BEN-2293:Placebo Safety, Tolerability, PK • Adaptive multiple ascending dose cohort design Includes efficacy endpoints • MALDI imaging To evaluate human skin PK Phase Ib: ✔ Successfully completed Safety and Tolerability arm BSA= Body surface area. QD = once per day dosing BID= twice per day dosing Cohort 1 0.25% QD 7 Days 10% BSA Not tolerated/ Inadequate SM Adaptive design for Phase Ib of the clinical study Cohort 3a 1% Cohort 2 1% QD 7 Days 10% BSA Terminate Study Tolerated/PK Supports SM Not tolerated/ Inadequate SM Tolerated/PK Supports SM QD 14 Days 30% BSA Not tolerated/ Inadequate SM Cohort 3b 0.25% QD 14 Days 30% BSA Not tolerated/ Inadequate SM Terminate Study Tolerated/PK Supports SM Tolerated/PK Supports SM Cohort 4a 1% BID 14 Days 30% BSA Cohort 4b 0.25% BID 14 Days 30% BSA Benevolent 46

View entire presentation